Form 8-K

8-K — MERIT MEDICAL SYSTEMS INC

Accession: 0000856982-26-000023

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0000856982

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — mmsi-20260430x8k.htm (Primary)

EX-99.1 (mmsi-20260430xex99d1.htm)

EX-99.2 (mmsi-20260430xex99d2.htm)

GRAPHIC (mmsi-20260430x8k001.jpg)

GRAPHIC (mmsi-20260430xex99d1001.jpg)

GRAPHIC (mmsi-20260430xex99d2g001.jpg)

GRAPHIC (mmsi-20260430xex99d2g002.jpg)

GRAPHIC (mmsi-20260430xex99d2g003.jpg)

GRAPHIC (mmsi-20260430xex99d2g004.jpg)

GRAPHIC (mmsi-20260430xex99d2g005.jpg)

GRAPHIC (mmsi-20260430xex99d2g006.jpg)

GRAPHIC (mmsi-20260430xex99d2g007.jpg)

GRAPHIC (mmsi-20260430xex99d2g008.jpg)

GRAPHIC (mmsi-20260430xex99d2g009.jpg)

GRAPHIC (mmsi-20260430xex99d2g010.jpg)

GRAPHIC (mmsi-20260430xex99d2g011.jpg)

GRAPHIC (mmsi-20260430xex99d2g012.jpg)

GRAPHIC (mmsi-20260430xex99d2g013.jpg)

GRAPHIC (mmsi-20260430xex99d2g014.jpg)

GRAPHIC (mmsi-20260430xex99d2g015.jpg)

GRAPHIC (mmsi-20260430xex99d2g016.jpg)

GRAPHIC (mmsi-20260430xex99d2g017.jpg)

GRAPHIC (mmsi-20260430xex99d2g018.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: mmsi-20260430x8k.htm · Sequence: 1

MERIT MEDICAL SYSTEMS INC_April 30, 2026

0000856982falseMERIT MEDICAL SYSTEMS INC00008569822026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 30, 2026

Merit Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

Utah

0-18592

87-0447695

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation or organization)

File Number)

Identification No.)

1600 West Merit Parkway

South Jordan, Utah

84095

(Address of principal executive offices)

(Zip Code)

(801) 253-1600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, no par value

MMSI

NASDAQ Global Select Market System

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On April 30, 2026, Merit Medical Systems, Inc. (“Merit”) issued a press release announcing its operating and financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On April 30, 2026, Merit is conducting a conference call to discuss its operating and financial results for the quarter ended March 31, 2026. A live webcast and slide presentation will also be available for the conference call on the Merit’s website. A copy of the slide presentation is furnished as Exhibit 99.2 to this report and incorporated herein by reference.

The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K (including the exhibits attached hereto) is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended, or the Exchange Act.

In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), Merit is disclosing non-GAAP financial information in both the press release announcing its operating and financial results and the conference call presentation. Reconciliations of certain of these non-GAAP financial measures to the comparable GAAP financial measures are included in the press release and conference call presentation attached as Exhibit 99.1 and 99.2, respectively, to this report. Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most directly comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP figures to their GAAP counterparts, could be confusing to investors or cause undue reliance.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

EXHIBIT NUMBER

DESCRIPTION

99.1

Press Release, dated April 30, 2026, entitled “Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance” including unaudited financial information.

99.2

Conference Call Presentation

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MERIT MEDICAL SYSTEMS, INC.

Date: April 30, 2026

By:

/s/ Brian G. Lloyd

Brian G. Lloyd

Chief Legal Officer and Corporate Secretary

EX-99.1

Filename: mmsi-20260430xex99d1.htm · Sequence: 2

Exhibit 99.1

Contacts:

PR/Media Inquiries:

Sarah Comstock

Merit Medical

Investor Inquiries:

Mike Piccinino, CFA, IRC

ICR Healthcare

+1-801-432-2864

+1-443-213-0509

sarah.comstock@merit.com

mike.piccinino@icrhealthcare.com

FOR IMMEDIATE RELEASE

MERIT MEDICAL REPORTS FIRST QUARTER 2026 RESULTS AND UPDATES FULL-YEAR GUIDANCE

Financial Highlights†

● Reported revenue of $381.9 million, up 7%

● Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively

o Constant currency revenue, organic* increased 4%, excluding revenue from divested product line

● GAAP operating margin of 11.6%, compared to 11.5% in prior year period

● Non-GAAP operating margin* of 19.7%, compared to 19.3% in prior year period

● GAAP EPS $0.68, up 39%

● Non-GAAP EPS* $0.94, up 9%

● Free cash flow* generation of $24.7 million, up 26%

Business Developments

● On February 17, 2026, Merit sold certain assets related to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25.5 million was paid in cash at closing

● On April 1, 2026, Merit acquired View Point Medical, Inc., manufacturer of the OneMark® Detection Imaging System and OneMark Tissue Markers, for $140 million, of which $90 million was paid in cash at closing

● Beginning in the first quarter of 2026, Merit reorganized the presentation of revenue into two product categories – Foundational and Therapeutic - to better reflect the clinical uses of our diverse portfolio of products**

† Comparisons above are calculated for the current quarter compared with the first quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.

* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

** Merit presented historical revenue information under the new product categories in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 13, 2026.

SOUTH JORDAN, Utah, April 30, 2026 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced financial results for the three-month period ended March 31, 2026.

“Merit delivered first quarter financial results that exceeded the high-end of our expectations,” said Martha G. Aronson, Merit’s President and CEO. “We delivered 3.7% organic, constant currency revenue growth, excluding the impact of a strategic divestiture. We also delivered solid improvement in our non-GAAP operating margin despite incremental year-over-year headwinds from tariffs, and growth in our non-GAAP earnings per share and free cash flow, which increased 9% and 26%, respectively, year-over-year.”

Ms. Aronson continued: “We are pleased with the solid start to 2026 and remain confident in the team’s ability to drive stable constant currency growth, improving profitability, and solid free cash flow in 2026, the final year of our Continued Growth Initiatives Program. Importantly, we continue to identify opportunities to enhance our long-term organic growth and profitability profile as evidenced by the strategic divestiture of a non-core product line in February and our acquisition of the OneMark System from View Point Medical on April 1, 2026. This acquisition expands Merit’s portfolio of therapeutic oncology products with a differentiated oncology offering, serving a large and growing market opportunity, and is expected to contribute margin-accretive growth going forward.”

Merit’s revenue by product category for the three-month periods ended March 31, 2026 and 2025 was as follows (unaudited; in thousands, except for percentages):

Three Months Ended

Reported

Constant Currency*

March 31,

Impact of foreign

March 31,

2026

2025

% Change

exchange

2026

% Change

Foundational

255,479

240,382

(4,989)

250,490

Therapeutic

126,398

114,969

(2,947)

123,451

Total

381,877

355,351

(7,936)

373,941

Financial Summary:

GAAP gross margin was 48.4%, compared to 48.4% for the first quarter of 2025. Non-GAAP gross margin* was 53.2%, compared to 53.4% for the first quarter of 2025.

GAAP operating margin was 11.6%, compared to 11.5% for the first quarter of 2025. Non-GAAP operating margin* was 19.7%, compared to 19.3% for the first quarter of 2025.

GAAP net income was $41.0 million, or $0.68 per share, compared to $30.1 million, or $0.49 per share, for the first quarter of 2025. Non-GAAP net income* was $56.7 million, or $0.94 per share, compared to $52.9 million, or $0.86 per share, for the first quarter of 2025.

As of March 31, 2026, Merit had cash and cash equivalents of $488.1 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million as of December 31, 2025. Merit had available borrowing capacity of approximately $697 million as of March 31, 2026.

Fiscal Year 2026 Financial Guidance

Based upon the information currently available to Merit’s management, for the twelve-months ending December 31, 2026, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today’s date, material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit anticipates the following financial results:

Revenue and Earnings Guidance*

Updated Guidance(2)

Prior Guidance(3)

Year Ending

% Change

Year Ending

% Change

Financial Measure

December 31, 2026

Y/Y

December 31, 2026

Y/Y

Total Revenue

$1.612 - $1.634 billion

6% - 8%

$1.610 - $1.630 billion

6% - 8%

Non-GAAP Earnings Per Share(1)

$4.01 - $4.15

5% - 8%

$4.01 - $4.15

5% - 8%

*Percentage figures approximated; dollar figures may not foot due to rounding.

(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”) calculated using the if-converted method of approximately $0.04 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.

(2) “Updated Guidance” reflects the impacts of Merit’s acquisition of View Point Medical, Inc. announced on April 1, 2026. Specifically, from the acquisition effective date of April 1, 2026 through December 31, 2026, the acquisition is projected to contribute revenue in the range of $2 million to $4 million and to dilute Merit’s “Prior Guidance” for non-GAAP earnings per share by approximately $0.05, inclusive of approximately $2.0 million of lower interest income on cash balances used for the total purchase consideration and excluding approximately $5.3 million of non-cash and non-recurring transaction-related expenses, and to be dilutive to Merit’s full-year 2026 GAAP net income and GAAP earnings per share.

(3) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on February 24, 2026.

Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit’s financial guidance for the year ending December 31, 2026 is subject to risks and uncertainties identified in this release and Merit’s filings with the SEC. This guidance is based on information and estimates available to Merit as of April 30, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.

CONFERENCE CALL

As previously announced, Merit will hold its investor conference call today, Thursday, April 30, 2026, at 4:30 p.m., Eastern Time, to discuss its results for the first quarter and provide an operational update. To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck will also be available at merit.com.

CONSOLIDATED BALANCE SHEETS

(in thousands)

March 31,

December 31,

2026

2025

ASSETS

(Unaudited)

Current Assets

Cash and cash equivalents

488,080

446,404

Trade receivables, net

206,446

203,710

Other receivables

18,717

17,773

Inventories

352,386

333,705

Prepaid expenses and other assets

29,274

31,493

Prepaid income taxes

5,033

4,941

Income tax refund receivables

1,838

2,128

Total current assets

1,101,774

1,040,154

Property and equipment, net

433,957

428,401

Intangible assets, net

511,995

537,654

Goodwill

503,432

506,837

Deferred income tax assets

7,085

7,049

Operating lease right-of-use assets

86,376

87,600

Other assets

74,665

78,227

Total Assets

2,719,284

2,685,922

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

Trade payables

67,853

60,551

Accrued expenses

122,515

159,486

Current operating lease liabilities

11,228

10,876

Income taxes payable

15,278

8,851

Total current liabilities

216,874

239,764

Long-term debt

735,160

734,038

Deferred income tax liabilities

19,664

19,665

Liabilities related to unrecognized tax benefits

2,248

Deferred compensation payable

17,373

17,542

Deferred credits

1,373

1,398

Long-term operating lease liabilities

75,175

76,658

Other long-term obligations

24,689

10,306

Total liabilities

1,092,556

1,101,619

Stockholders' Equity

Common stock

769,271

763,909

Retained earnings

865,025

824,030

Accumulated other comprehensive loss

(7,568)

(3,636)

Total stockholders' equity

1,626,728

1,584,303

Total Liabilities and Stockholders' Equity

2,719,284

2,685,922

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited, in thousands except per share amounts)

Three Months Ended

March 31,

2026

2025

Net sales

381,877

355,351

Cost of sales

197,080

183,331

Gross profit

184,797

172,020

Operating expenses:

Selling, general and administrative

118,210

107,486

Research and development

22,609

22,478

Contingent consideration (benefit) expense

(179)

1,023

Total operating expenses

140,640

130,987

Income from operations

44,157

41,033

Other income (expense):

Interest income

3,900

3,790

Interest expense

(6,526)

(6,568)

Other income (expense) — net

12,015

(297)

Total other income (expense) — net

9,389

(3,075)

Income before income taxes

53,546

37,958

Income tax expense

12,551

7,811

Net income

40,995

30,147

Earnings per common share

Basic

0.69

0.51

Diluted

0.68

0.49

Weighted average shares outstanding

Basic

59,510

58,897

Diluted

60,013

61,278

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

Three Months Ended

March 31,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

40,995

30,147

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

30,496

29,292

Gain on disposition of a business

(12,502)

—

Amortization of right-of-use operating lease assets

2,854

2,984

Fair value adjustments related to contingent consideration liabilities

(179)

1,023

Stock-based compensation expense

8,961

9,078

Other adjustments

2,123

1,507

Changes in operating assets and liabilities, net of acquisitions and divestitures

(32,067)

(33,459)

Total adjustments

(314)

10,425

Net cash, cash equivalents, and restricted cash provided by operating activities

40,681

40,572

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures for property and equipment

(16,009)

(21,061)

Proceeds from asset and business dispositions

25,500

—

Cash paid for notes receivable and other investments

—

(7,117)

Cash paid in acquisitions, net of cash acquired

(1,000)

Other investing, net

(757)

(457)

Net cash, cash equivalents, and restricted cash provided by (used in) investing activities

7,734

(29,635)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of common stock

2,775

13,152

Contingent payments related to acquisitions

(2,142)

(52)

Payment of taxes related to an exchange of common stock

(6,922)

(6,145)

Net cash, cash equivalents, and restricted cash (used in) provided by financing activities

(6,289)

6,955

Effect of exchange rates on cash

(426)

936

Net increase in cash, cash equivalents and restricted cash

41,700

18,828

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

Beginning of period

448,549

378,767

End of period

490,249

397,595

RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:

Cash and cash equivalents

488,080

395,529

Restricted cash reported in prepaid expenses and other current assets

2,169

2,066

Total cash, cash equivalents and restricted cash

490,249

397,595

Non-GAAP Financial Measures

Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that the non-GAAP financial measures referenced in this release may provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations. Non-GAAP financial measures used in this release include:

● constant currency revenue;

● constant currency revenue, organic;

● non-GAAP gross profit and margin;

● non-GAAP operating income and margin;

● non-GAAP net income;

● non-GAAP earnings per share; and

● free cash flow.

Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating and financial results to prior periods, to evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP.

Readers should consider non-GAAP measures used in this release in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit’s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies. Merit urges readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Merit’s business or results of operations.

Constant Currency Revenue

Merit’s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. dollar. The constant currency revenue adjustment of $(7.9) million to reported revenue for the three-month period ended March 31, 2026 was calculated using the applicable average foreign exchange rates for the three-month period ended March 31, 2025.

Constant Currency Revenue, Organic

Merit’s constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue. With respect to current fiscal year periods, constant currency revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions. For the three-month period ended March 31, 2026, Merit’s constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) the assets acquired from Pentax of America, Inc. related to the C2 CryoBalloon™ device in November 2025 (the “C2 Acquisition”) and (ii) Merit’s merger transaction with Biolife Delaware, L.L.C. (“Biolife”) in May 2025 (the “Biolife Merger”).

Non-GAAP Gross Profit and Margin

Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets. Non-GAAP gross margin is calculated by dividing non-GAAP gross profit by reported net sales.

Non-GAAP Operating Income and Margin

Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit’s management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.

Non-GAAP Net Income

Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to debt issuance costs, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and other items set forth in the tables below.

Non-GAAP EPS

Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

Free Cash Flow

Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows.

Other Non-GAAP Financial Measure Reconciliations

The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit’s corresponding financial measures prepared in accordance with GAAP, in each case, for the three-month periods ended March 31, 2026 and 2025. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of $3.2 million and $4.3 million for the three-month periods ended March 31, 2026 and 2025, respectively.

Reconciliation of GAAP Net Income to Non-GAAP Net Income

(Unaudited, in thousands except per share amounts)

Three Months Ended

March 31, 2026

Pre-Tax

Tax Impact

After-Tax

Per Share Impact

GAAP net income

53,546

(12,551)

40,995

0.68

Non-GAAP adjustments:

Cost of Sales

Amortization of intangibles

18,227

(4,303)

13,924

0.23

Operating Expenses

Contingent consideration benefit

(179)

(141)

(0.00)

Amortization of intangibles

2,454

(579)

1,875

0.03

Performance-based share-based compensation (a)

5,808

(306)

5,502

0.09

Acquisition-related

4,243

(711)

3,532

0.06

Medical Device Regulation expenses (b)

618

(146)

472

0.01

Other (Income) Expense

Amortization of long-term debt issuance costs

1,414

(334)

1,080

0.02

Gain on disposal of business unit

(12,502)

1,520

(10,982)

(0.18)

Other non-operating loss (d)

531

(125)

406

0.01

Non-GAAP net income

74,160

(17,497)

56,663

0.94

Diluted shares

60,013

Three Months Ended

March 31, 2025

Pre-Tax

Tax Impact

After-Tax

Per Share Impact

GAAP net income

37,958

(7,811)

30,147

0.49

Non-GAAP adjustments:

Cost of Sales

Amortization of intangibles

17,606

(4,160)

13,446

0.22

Operating Expenses

Contingent consideration expense

1,023

1,032

0.02

Amortization of intangibles

2,394

(566)

1,828

0.03

Performance-based share-based compensation (a)

4,774

(586)

4,188

0.07

Acquisition-related

(4)

0.00

Medical Device Regulation expenses (b)

1,594

(377)

1,217

0.02

Other (c)

(21)

(16)

(0.00)

Other (Income) Expense

Amortization of long-term debt issuance costs

1,414

(334)

1,080

0.02

Non-GAAP net income

66,758

(13,824)

52,934

0.86

Diluted shares

61,278

Note: Certain per-share impacts may not sum to totals due to rounding.

Reconciliation of Reported Operating Income to Non-GAAP Operating Income

(Unaudited, in thousands except percentages)

Three Months Ended

March 31, 2026

March 31, 2025

Amounts

% Sales

Amounts

% Sales

Net Sales as Reported

381,877

355,351

GAAP Operating Income

44,157

11.6

41,033

11.5

Cost of Sales

Amortization of intangibles

18,227

4.8

17,606

5.0

Operating Expenses

Contingent consideration (benefit) expense

(179)

(0.0)

1,023

0.3

Amortization of intangibles

2,454

0.6

2,394

0.7

Performance-based share-based compensation (a)

5,808

1.5

4,774

1.3

Acquisition-related

4,243

1.1

0.0

Medical Device Regulation expenses (b)

618

0.2

1,594

0.4

Other (c)

—

(21)

(0.0)

Non-GAAP Operating Income

75,328

19.7

68,419

19.3

Note: Certain percentages may not sum to totals due to rounding.

(a) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.

(b) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation.

(d) Includes equity method investment loss (income) from equity investees.

Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP)

(Unaudited, in thousands except percentages)

Three Months Ended

March 31,

% Change

2026

2025

Reported Revenue

7.5

381,877

355,351

Add: Impact of foreign exchange

(7,936)

—

Constant Currency Revenue (a)

5.2

373,941

355,351

Less: Revenue from certain acquisitions

(9,044)

—

Constant Currency Revenue, Organic (a)

2.7

364,897

355,351

Less: Revenue from divested product line, DualCap® (b)

(1,644)

(4,916)

Constant Currency Revenue, Organic, excluding impact of divested product line (a)

3.7

363,253

350,435

(a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this release entitled “Non-GAAP Financial Measures.”

(b) On February 17, 2026, Merit sold certain assets relating to the DualCap® product line to Health Line International Corporation for a purchase price of $28 million, of which $25.5 million was paid at closing.

Reconciliation of Reported Gross Margin to Non-GAAP Gross Margin (Non-GAAP)

(Unaudited, as a percentage of reported revenue)

Three Months Ended

March 31,

2026

2025

Reported Gross Margin

48.4

Add back impact of:

Amortization of intangibles

4.8

5.0

Non-GAAP Gross Margin

53.2

53.4

Note: Certain percentages may not sum to totals due to rounding.

Reconciliation of Reported Cash Flow from Operations to Free Cash Flow (Non-GAAP)

(Unaudited, in thousands)

Three Months Ended

March 31,

2026

2025

Reported Cash Flow from Operations

40,681

40,572

Less: Capital Expenditures

(16,009)

(21,061)

Free Cash Flow

24,672

19,511

Reconciliation of 2026 Net Sales Guidance - % Change from Prior Year (Constant Currency)

Updated Guidance

Prior Guidance(1)

Low

High

Low

High

2026 Net Sales Guidance - % Change from Prior Year (GAAP)

6.3%

7.8%

6.2%

7.5%

Estimated impact of foreign currency exchange rate fluctuations

(0.8%)

2026 Net Sales Guidance - % Change from Prior Year (Constant Currency)

5.6%

7.0%

5.4%

6.7%

Note: Certain percentages may not sum to totals due to rounding.

(1) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on February 24, 2026.

ABOUT MERIT

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:

● statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,” “continue,” “upcoming,” “optimistic” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;

● statements that address Merit’s future operating performance or events or developments that Merit’s management expects or anticipates will occur, including, without limitation, any statements regarding Merit’s projected revenues, earnings or other future financial measures, Merit’s plans and objectives for future operations, Merit’s proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit’s Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and

● statements regarding Merit’s past performance, efforts, or results about which inferences or assumptions may be made, including statements proceeded or followed by the words "preliminary," "initial," "potential," "possible," "diligence," "industry-leading," "compliant," "indications" or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.

The forward-looking statements contained in this release are based on Merit management’s current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and may differ materially, from Merit’s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

The following are some of the important risks and uncertainties that could cause Merit’s actual results to differ from management’s expectations in any forward-looking statements: risks and uncertainties associated with Merit’s executive succession planning activities and leadership transition; risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed, prospective or invalidated tariffs, duties or other measures; risks and uncertainties associated with Merit’s integration of businesses or assets acquired from third parties, including View Point Medical, Inc. in April 2026, the business and assets relating to the C2 CryoBalloon™ device acquired from Pentax of America, Inc. in November 2025, Biolife Delaware, L.L.C. in May 2025 and the businesses and assets acquired from Cook Medical Holdings LLC in November 2024 and from EndoGastric Solutions, Inc. in July 2024, and Merit’s ability to achieve the anticipated financial results, product development and other anticipated benefits of such acquisitions; effects of the Convertible Notes on Merit’s net income and earnings per share performance; disruptions in Merit’s supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; fluctuations in interest or foreign currency exchange rates and inflation; cybersecurity events; government scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit’s products; the safety, efficacy and patient and physician adoption of Merit’s products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit’s products; litigation and other legal proceedings affecting Merit; failure to comply with U.S. and foreign laws and regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the assertion that Merit’s technology infringes the

rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations; Merit’s divestiture of its DualCap® anti microbial cap product line in February 2026; changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit’s effective tax rate; termination of relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties which may affect Merit’s business, operations and financial condition, see Part I, Item 1A. “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC, which Merit updated in Part II, Item 1A. “Risk Factors” in Merit’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

# # #

EX-99.2

Filename: mmsi-20260430xex99d2.htm · Sequence: 3

Exhibit 99.2

Merit Medical Investor Call

April 30, 2026

First Quarter

2026 Results

Martha Aronson

President and CEO

Raul Parra

CFO

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking

statements include, among others:  statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,” “continue,”

“upcoming,” “optimistic” or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;  statements that address Merit’s future operating performance or events or developments that Merit’s management expects or anticipates will occur, including, without limitation, any statements regarding Merit’s

projected revenues, earnings or other future financial measures, Merit’s plans and objectives for future operations, Merit’s proposed new products or services, the integration, development or commercialization of the

business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit’s Continued Growth Initiatives Program or other

business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and

 statements regarding Merit’s past performance, efforts, or results about which inferences or assumptions may be made, including statements proceeded or followed by the words "preliminary," "initial," "potential,"

"possible," "diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.

inaccurate, or risks or uncertainties materialize, actual results will likely differ, and may differ materially, from Merit’s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are

not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.

executive succession planning activities and leadership transition; risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed, prospective or

invalidated tariffs, duties or other measures; risks and uncertainties associated with Merit’s integration of businesses or assets acquired from third parties, including View Point Medical, Inc. in April 2026, the business and assets

relating to the C2 CryoBalloon device acquired from Pentax of America, Inc. in November 2025 (the “C2 Acquisition”), Biolife Delaware, L.L.C. in May 2025 (the “Biolife Merger”) and the businesses and assets acquired from

Cook Medical Holdings LLC in November 2024 and from EndoGastric Solutions, Inc. in July 2024, and Merit’s ability to achieve the anticipated financial results, product development and other anticipated benefits of such

acquisitions; effects of the Convertible Notes on Merit’s net income and earnings per share performance; disruptions in Merit’s supply chain, manufacturing or sterilization processes; U.S. and global political, economic,

competitive, reimbursement and regulatory conditions; modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies; reduced availability of, and price

increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit’s potential inability to successfully manage growth through acquisitions generally, including the inability

to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; fluctuations in interest or foreign currency exchange

rates and inflation; cybersecurity events; government scrutiny and regulation of the medical device industry; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit’s products;

the safety, efficacy and patient and physician adoption of Merit’s products; the ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to Merit’s products; litigation and other legal

proceedings affecting Merit; failure to comply with U.S. and foreign laws and regulations; restrictions on Merit’s liquidity or business operations resulting from its debt agreements; infringement of Merit’s technology or the

assertion that Merit’s technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations; Merit’s divestiture of its DualCap® anti microbial

cap product line in February 2026; changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect Merit’s effective tax rate; termination of

relationships with Merit’s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit’s existing or future products obsolete; market acceptance of new products; failure

to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of

the risks and uncertainties which may affect Merit’s business, operations and financial condition, see Part I, Item 1A. “Risk Factors” in Merit’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC,

which Merit updated in Part II, Item 1A. “Risk Factors” in Merit’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this

release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.

NON-GAAP FINANCIAL MEASURES

Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of

America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures provide investors with useful information

regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period

comparisons of such operations. Certain financial measures included in this presentation, or which may be referenced in

management’s discussion of Merit’s historical and future operations and financial results, have not been calculated in accordance with

GAAP, and, therefore, are referenced as non-GAAP financial measures. Readers should consider non-GAAP measures used in this

presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP

financial measures generally exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to

inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Additionally, non-GAAP

financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges

readers to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely

on any single financial measure to evaluate Merit’s business or results of operations. Please refer to “Notes to Non-GAAP Financial

Measures” at the end of these materials for more information.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its

subsidiaries, or its licensors.

GAAP NON-GAAP*

Q1 2026 Q1 2025 % Change Q1 2026 Q1 2025 % Change

Revenue $381.9M $355.4M 7.5% $364.9M†

$355.4M 2.7%

Gross Margin 48.4% 48.4% — 53.2% 53.4% (0.4)%

Operating Margin 11.6% 11.5% 0.1% 19.7% 19.3% 2.5%

Net Income $41.0M $30.1M 36.0% $56.7M $52.9M 7.0%

Earnings per Share $0.68 $0.49 38.8% $0.94 $0.86 9.3%

Financial Summary

Note: Amounts in this presentation are rounded while percentages are calculated from the underlying amounts. * See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.

† A non-GAAP financial measure, representing constant currency revenue, organic.

In millions, except per share amounts and percentages

Revenue Breakdown

Region Q1 2026 Q1 2025 $ Change % Change CC % Change*

Domestic $226,516 $213,564 $12,952 6.1% 6.8%

International 155,361 141,787 13,574 9.6% 2.9%

Total $381,877 $355,351 $26,526 7.5% 5.2%

* A non-GAAP financial measure, representing revenue growth on a constant currency (“CC”) basis. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.

In thousands, except percentages

Financial Metrics

Metric Q1 2026 Q1 2025

Depreciation & Amortization $30.5M $29.3M

Stock Comp (performance-based) 5.8M 4.8M

Stock Comp (not performance-based) 3.2M 4.3M

Operating Cash Flow 40.7M 40.6M

Capital Expenditures-Property and Equipment 16.0M 21.1M

In millions

Fiscal Year 2026 Financial Guidance

financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses related to

acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based

stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry

regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of

the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a

reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

Merit’s financial guidance for the year ending December 31, 2026, is subject to risks and uncertainties identified in this presentation and Merit’s filings with the U.S. Securities and Exchange Commission (the “SEC”).

This guidance is based on information and estimates available to Merit as of April 30, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results

will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.

(1) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on February 24, 2026.

* Percentage figures approximated; percentage and dollar figures may not foot due to rounding

2026 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation*

Revenue and Earnings Guidance*

(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 calculated

using the if-converted method of approximately $0.04 per share for the year ending December 31, 2026. Any offsetting

impacts of the capped call associated with the Convertible Notes are not considered.

(2) “Updated Guidance” reflects the impacts of Merit’s acquisition of View Point Medical, Inc. announced on April 1, 2026.

Specifically, from the acquisition effective date of April 1, 2026 through December 31, 2026, the acquisition is projected to

contribute revenue in the range of $2 million to $4 million and to dilute Merit’s “Prior Guidance” for non-GAAP earnings

per share by approximately $0.05, inclusive of approximately $2.0 million of lower interest income on cash balances used

for the total purchase consideration and excluding approximately $5.3 million of non-cash and non-recurring transaction-related expenses, and to be dilutive to Merit’s full-year 2026 GAAP net income and GAAP earnings per share.

(3) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on February 24, 2026.

Low High Low High

2026 Net Sales Guidance - % Change from Prior Year (GAAP) 6.3% 7.8% 6.2% 7.5%

Estimated impact of foreign currency exchange rate fluctuations (0.8%) (0.8%) (0.8%) (0.8%)

2026 Net Sales Guidance - % Change from Prior Year (Constant Currency) 5.6% 7.0% 5.4% 6.7%

Updated Guidance Prior Guidance(1)

Year Ending % Change Year Ending % Change

Financial Measure December 31, 2026 Y/Y December 31, 2026 Y/Y

Total Revenue $1.612 - $1.634 billion 6% - 8% $1.610 - $1.630 billion 6% - 8%

Non-GAAP Earnings Per Share(1) $4.01 - $4.15 5% - 8% $4.01 - $4.15 5% - 8%

Updated Guidance(2) Prior Guidance(3)

Appendix

Notes to Non-GAAP Financial Measures

For additional details, please see the accompanying press release and forward-looking statement disclosure.

These presentation materials and associated commentary from Merit’s management, as well as the press release issued today, use non-GAAP financial measures, including:

• constant currency revenue;

• constant currency revenue, organic;

• non-GAAP gross profit and margin;

• non-GAAP operating income and margin;

• non-GAAP net income;

• non-GAAP earnings per share; and

• free cash flow.

Merit’s management team uses these non-GAAP financial measures to evaluate Merit’s profitability and efficiency, to compare operating and financial results to prior periods, to

evaluate changes in the results of its operating segments, and to measure and allocate financial resources internally. However, Merit’s management does not consider such non-GAAP

measures in isolation or as an alternative to measures determined in accordance with GAAP.

exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP gross profit and margin, non-GAAP operating income and margin, non-GAAP net income, and non-GAAP earnings per share (in each case, as further illustrated in the reconciliation tables below) because such

amounts in any specific period may not directly correlate to the underlying performance of Merit’s business operations and can vary significantly between periods as a result of

factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain

employee termination benefits, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes

in tax or industry regulations, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and debt issuance costs. Merit may incur

similar types of expenses in the future, and the non-GAAP financial information included in this release should not be viewed as a statement or indication that these types of

expenses will not recur. Additionally, the non-GAAP financial measures used in this release may not be comparable with similarly titled measures of other companies. Merit urges

readers to review the reconciliations of its non-GAAP financial measures to their most directly comparable GAAP financial measures included herein, and not to rely on any single

financial measure to evaluate Merit’s business or results of operations.

Notes to Non-GAAP Financial Measures (cont.)

Constant Currency Revenue

Merit’s constant currency revenue is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at

the applicable foreign exchange rates in effect during the comparable prior-year period and adjusting for the effects of hedging transactions on reported revenue, which are recorded

in the U.S. dollar. The constant currency revenue adjustment of ($7.9) million to reported revenue for the three-month period ended March 31, 2026 was calculated using the

applicable average foreign exchange rates for the three-month period ended March 31, 2025.

Constant Currency Revenue, Organic

Merit’s constant currency revenue, organic, is defined, with respect to prior fiscal year periods, as GAAP revenue. With respect to current fiscal year periods, constant currency

revenue, organic, is defined as constant currency revenue (as defined above), less revenue from certain acquisitions. For the three-month period ended March 31, 2026, Merit’s

constant currency revenue, organic, excludes revenues attributable to products acquired in connection with (i) the C2 Acquisition and (ii) the Biolife Merger.

Non-GAAP Gross Profit and Margin

Non-GAAP gross profit is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets. Non-GAAP gross margin is calculated by dividing

non-GAAP gross profit by reported net sales.

Non-GAAP Operating Income and Margin

Non-GAAP operating income is calculated by adjusting GAAP operating income for certain items which are deemed by Merit’s management to be outside of core operations and

vary in amount and frequency among periods, such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of

previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary

course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations, as well as other items

referenced in the tables below. Non-GAAP operating margin is calculated by dividing non-GAAP operating income by reported net sales.

Notes to Non-GAAP Financial Measures (cont.)

Non-GAAP Net Income

Non-GAAP net income is calculated by adjusting GAAP net income for the items set forth in the definition of non-GAAP operating income above, as well as for expenses related to

debt issuance costs, gains or losses on disposal of certain assets, equity method investment loss (income) from equity investees, and other items set forth in the tables below.

Non-GAAP EPS

Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

Free Cash Flow

Free cash flow is defined as cash flow from operations calculated in accordance with GAAP, less capital expenditures for property and equipment calculated in accordance with

GAAP, as set forth in the consolidated statement of cash flows.

Other Non-GAAP Financial Measure Reconciliations

The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP financial measures to Merit’s corresponding financial measures prepared

in accordance with GAAP, in each case, for the three-month periods ended March 31, 2026 and 2025. The non-GAAP income adjustments referenced in the following tables do not

reflect non-performance-based stock compensation expense of $3.2 million and $4.3 million for the three-month periods ended March 31, 2026 and 2025, respectively.

Reconciliation of GAAP Net Income to Non-GAAP Net Income

(Unaudited; in thousands except per share amounts)

Note: Certain per-share impacts may not sum to totals due to rounding.

GAAP net income $ 53,546 $ (12,551) $ 40,995 $ 0.68 $ 37,958 $ (7,811) $ 30,147 $ 0.49 Non-GAAP adjustments: Cost of Sales

Amortization of intangibles 18,227 (4,303) 13,924 0.23 17,606 (4,160) 13,446 0.22 Operating Expenses

Contingent consideration (benefit) expense (179) 38 (141) (0.00) 1,023 9 1,032 0.02 Amortization of intangibles 2,454 (579) 1,875 0.03 2,394 (566) 1,828 0.03 Performance-based share-based compensation (a) 5,808 (306) 5,502 0.09 4,774 (586) 4,188 0.07 Acquisition-related 4,243 (711) 3,532 0.06 16 (4) 12 0.00 Medical Device Regulation expenses (b) 618 (146) 472 0.01 1,594 (377) 1,217 0.02 Other (c) — — — — (21) 5 (16) (0.00) Other (Income) Expense

Amortization of long-term debt issuance costs 1,414 (334) 1,080 0.02 1,414 (334) 1,080 0.02 Gain on disposal of business unit (12,502) 1,520 (10,982) (0.18) — — — — Other non-operating loss (d) 531 (125) 406 0.01 — — — — Non-GAAP net income $ 74,160 $ (17,497) $ 56,663 $ 0.94 $ 66,758 $ (13,824) $ 52,934 $ 0.86 Diluted shares 60,013 61,278

Three Months Ended Three Months Ended

March 31, 2026 March 31, 2025

Pre-Tax Tax Impact After-Tax Per Share Impact Pre-Tax Tax Impact After-Tax Per Share Impact

Reconciliation of GAAP Operating Income to Non-GAAP Operating Income

(Unaudited; in thousands except percentages)

Note: Certain percentages may not sum to totals due to rounding.

Net Sales as Reported $ 381,877 $ 355,351

GAAP Operating Income 44,157 11.6 % 41,033 11.5 %

Cost of Sales

Amortization of intangibles 18,227 4.8 % 17,606 5.0 %

Operating Expenses

Contingent consideration (benefit) expense (179) (0.0) % 1,023 0.3 %

Amortization of intangibles 2,454 0.6 % 2,394 0.7 %

Performance-based share-based compensation (a) 5,808 1.5 % 4,774 1.3 %

Acquisition-related 4,243 1.1 % 16 0.0 %

Medical Device Regulation expenses (b) 618 0.2 % 1,594 0.4 %

Other (c) — — (21) (0.0) %

Non-GAAP Operating Income $ 75,328 19.7 % $ 68,419 19.3 %

Three Months Ended Three Months Ended

March 31, 2026 March 31, 2025

Amounts % Sales Amounts % Sales

Footnotes to Reconciliations of GAAP Net Income to Non-GAAP Net Income and

GAAP Operating Income to Non-GAAP Operating Income

a) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.

b) Represents incremental expenses incurred to comply with the E.U. Medical Device Regulation.

c) Represents costs to comply with Merit’s corporate integrity agreement with the U.S. Department of Justice.

d) Includes equity method investment loss (income) from equity investees.

Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant

Currency Revenue, Organic (Non-GAAP)

(Unaudited; in thousands except percentages)

(a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this presentation entitled “Notes to

Non-GAAP Financial Measures.”

(b) On February 17, 2026, Merit sold certain assets relating to the DualCap® product line to Health Line International Corporation for a purchase price of

$28 million, of which $25.5 million was paid at closing.

% Change

Reported Revenue 7.5 % $ 381,877 $ 355,351 Add: Impact of foreign exchange (7,936) — Constant Currency Revenue (a) 5.2 % $ 373,941 $ 355,351 Less: Revenue from certain acquisitions — (9,044) Constant Currency Revenue, Organic (a) 2.7 % $ 364,897 $ 355,351 Less: Revenue from divested product line, DualCap® (b) (4,916) (1,644) Constant Currency Revenue, Organic, excluding impact of divested product line (a) 3.7 % $ 363,253 $ 350,435

Three Months Ended

March 31,

2026 2025

Reconciliation of GAAP Gross Margin to Non-GAAP Gross Margin

(Unaudited; as a percentage of reported revenue)

Note: Certain percentages may not sum to totals due to rounding.

2026 2025

Reported Gross Margin 48.4 % 48.4 %

Add back impact of: Amortization of intangibles 4.8 % 5.0 %

Non-GAAP Gross Margin % 53.4 53.2 %

March 31,

Three Months Ended

Reconciliation of Reported Cash Flow from Operations to Free Cash Flow

(Unaudited; in thousands)

Reported Cash Flow from Operations $ 40,681 $ 40,572 Less: Capital Expenditures (21,061) (16,009) Free Cash Flow $ 24,672 $ 19,511 Three Months Ended

March 31,

2026 2025

GRAPHIC

Filename: mmsi-20260430x8k001.jpg · Sequence: 4

Binary file (11531 bytes)

Download mmsi-20260430x8k001.jpg

GRAPHIC

Filename: mmsi-20260430xex99d1001.jpg · Sequence: 5

Binary file (32443 bytes)

Download mmsi-20260430xex99d1001.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g001.jpg · Sequence: 6

Binary file (100504 bytes)

Download mmsi-20260430xex99d2g001.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g002.jpg · Sequence: 7

Binary file (287475 bytes)

Download mmsi-20260430xex99d2g002.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g003.jpg · Sequence: 8

Binary file (160242 bytes)

Download mmsi-20260430xex99d2g003.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g004.jpg · Sequence: 9

Binary file (85165 bytes)

Download mmsi-20260430xex99d2g004.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g005.jpg · Sequence: 10

Binary file (68700 bytes)

Download mmsi-20260430xex99d2g005.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g006.jpg · Sequence: 11

Binary file (58342 bytes)

Download mmsi-20260430xex99d2g006.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g007.jpg · Sequence: 12

Binary file (171918 bytes)

Download mmsi-20260430xex99d2g007.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g008.jpg · Sequence: 13

Binary file (17914 bytes)

Download mmsi-20260430xex99d2g008.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g009.jpg · Sequence: 14

Binary file (160495 bytes)

Download mmsi-20260430xex99d2g009.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g010.jpg · Sequence: 15

Binary file (142819 bytes)

Download mmsi-20260430xex99d2g010.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g011.jpg · Sequence: 16

Binary file (96536 bytes)

Download mmsi-20260430xex99d2g011.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g012.jpg · Sequence: 17

Binary file (107413 bytes)

Download mmsi-20260430xex99d2g012.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g013.jpg · Sequence: 18

Binary file (67241 bytes)

Download mmsi-20260430xex99d2g013.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g014.jpg · Sequence: 19

Binary file (61273 bytes)

Download mmsi-20260430xex99d2g014.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g015.jpg · Sequence: 20

Binary file (78424 bytes)

Download mmsi-20260430xex99d2g015.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g016.jpg · Sequence: 21

Binary file (39494 bytes)

Download mmsi-20260430xex99d2g016.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g017.jpg · Sequence: 22

Binary file (37149 bytes)

Download mmsi-20260430xex99d2g017.jpg

GRAPHIC

Filename: mmsi-20260430xex99d2g018.jpg · Sequence: 23

Binary file (44096 bytes)

Download mmsi-20260430xex99d2g018.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 28

v3.26.1

Document and Entity Information

Apr. 30, 2026

Document and Entity Information [Abstract]

Document Type

8-K

Document Period End Date

Apr. 30, 2026

Entity File Number

0-18592

Entity Registrant Name

MERIT MEDICAL SYSTEMS INC

Entity Incorporation, State or Country Code

Entity Tax Identification Number

87-0447695

Entity Address, Address Line One

1600 West Merit Parkway

Entity Address, City or Town

South Jordan

Entity Address, State or Province

Entity Address, Postal Zip Code

84095

City Area Code

801

Local Phone Number

253-1600

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, no par value

Trading Symbol

MMSI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Central Index Key

0000856982

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration